|
DUBAI, UAE, Sept. 24, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, has released its latest Bybit Crypto Insights report, analyzing the growth of decentralized perpetual exchanges and how Aster has emerged as a competitor to Hyperliquid.
Bybit has entered the onchain DEX race with Byreal, a Solana-based decentralized exchange now in beta and set for mainnet in early October. According to DefiLlama, Byreal has recorded more than $335.41M in cumulative trading volume since its beta launch, with daily volume peaking at $28.15M. TVL reached a high of $14.22M. Byreal uses hybrid liquidity models, including RFQ and CLMM mechanisms, to reduce slippage and curb MEV.
The Rise of Aster
Aster was formed from the merger of Astherus and ApolloX and launched in September with a token that surged more than 300 percent in hours. The ASTER token reached a $1.33 billion market cap within two days. Aster's features include MEV-free execution, hidden orders and dual trading interfaces designed for both retail and professional users. Plans for a zero-knowledge-powered chain and integration with the Binance ecosystem have strengthened its early positioning.
How Aster stacks up against Hyperliquid
Hyperliquid remains the leading decentralized perp DEX, recording about $200 billion in September trading volume compared with Aster's $20 billion. Its market capitalization is estimated at $13.2 billion, while Aster's is about $2.5 billion.
The two platforms reflect contrasting strategies. Hyperliquid built its own Layer 1 infrastructure with HyperBFT consensus and sub-second finality, delivering centralized exchange-like execution entirely on chain. Aster was mainly launched on BNB Chain with a modular design and emphasizes ecosystem integration, branding and token-driven growth.
How is Hyperliquid different from dYdX/GMX?
Legacy platforms such as dYdX and GMX emphasize decentralization as a core principle. By comparison, newer players like Hyperliquid and Aster prioritize speed, liquidity and user experience. Both sacrifice a degree of decentralization in favor of performance.
Hyperliquid and beyond
Bybit's report notes that ideals such as trustlessness and community governance are taking a back seat to execution and user experience. Hyperliquid has long been the sector's benchmark, having developed a blockchain optimized for trading, with fully on-chain matching and sub-second settlement.
Aster, however, has gained visibility not by building new infrastructure but by capturing attention through narrative, exchange backing and incentives. Its rapid rise illustrates how token launches, partnerships and endorsements can shift market dynamics.
The road ahead
The report concludes that decentralized perpetual DEXs are evolving into a model where decentralization is treated as a feature rather than a foundation. With centralized exchanges capable of launching their own versions, competition is expected to increase.
Hyperliquid, once seen as untouchable, now faces an existential challenge. Its infrastructure remains strong, but the market increasingly rewards storytelling, ecosystem incentives and cultural resonance alongside technical performance.
Read more about Aster's emergence, Hyperliquid's position and the evolving landscape of decentralized perpetual exchanges in the Bybit Crypto Insights Report: The rise of decentralized perp DEXs: How Aster matches Hyperliquid.
#Bybit / #TheCryptoArk /#BybitResearch
About Bybit
Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit's Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
DUBAI, UAE, Sept. 24, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, has released its latest Bybit Crypto Insights report, analyzing the growth of decentralized perpetual exchanges and how Aster has emerged as a competitor to Hyperliquid.
Bybit has entered the onchain DEX race with Byreal, a Solana-based decentralized exchange now in beta and set for mainnet in early October. According to DefiLlama, Byreal has recorded more than $335.41M in cumulative trading volume since its beta launch, with daily volume peaking at $28.15M. TVL reached a high of $14.22M. Byreal uses hybrid liquidity models, including RFQ and CLMM mechanisms, to reduce slippage and curb MEV.
The Rise of Aster
Aster was formed from the merger of Astherus and ApolloX and launched in September with a token that surged more than 300 percent in hours. The ASTER token reached a $1.33 billion market cap within two days. Aster's features include MEV-free execution, hidden orders and dual trading interfaces designed for both retail and professional users. Plans for a zero-knowledge-powered chain and integration with the Binance ecosystem have strengthened its early positioning.
How Aster stacks up against Hyperliquid
Hyperliquid remains the leading decentralized perp DEX, recording about $200 billion in September trading volume compared with Aster's $20 billion. Its market capitalization is estimated at $13.2 billion, while Aster's is about $2.5 billion.
The two platforms reflect contrasting strategies. Hyperliquid built its own Layer 1 infrastructure with HyperBFT consensus and sub-second finality, delivering centralized exchange-like execution entirely on chain. Aster was mainly launched on BNB Chain with a modular design and emphasizes ecosystem integration, branding and token-driven growth.
How is Hyperliquid different from dYdX/GMX?
Legacy platforms such as dYdX and GMX emphasize decentralization as a core principle. By comparison, newer players like Hyperliquid and Aster prioritize speed, liquidity and user experience. Both sacrifice a degree of decentralization in favor of performance.
Hyperliquid and beyond
Bybit's report notes that ideals such as trustlessness and community governance are taking a back seat to execution and user experience. Hyperliquid has long been the sector's benchmark, having developed a blockchain optimized for trading, with fully on-chain matching and sub-second settlement.
Aster, however, has gained visibility not by building new infrastructure but by capturing attention through narrative, exchange backing and incentives. Its rapid rise illustrates how token launches, partnerships and endorsements can shift market dynamics.
The road ahead
The report concludes that decentralized perpetual DEXs are evolving into a model where decentralization is treated as a feature rather than a foundation. With centralized exchanges capable of launching their own versions, competition is expected to increase.
Hyperliquid, once seen as untouchable, now faces an existential challenge. Its infrastructure remains strong, but the market increasingly rewards storytelling, ecosystem incentives and cultural resonance alongside technical performance.
Read more about Aster's emergence, Hyperliquid's position and the evolving landscape of decentralized perpetual exchanges in the Bybit Crypto Insights Report: The rise of decentralized perp DEXs: How Aster matches Hyperliquid.
#Bybit / #TheCryptoArk /#BybitResearch
About Bybit
Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit's Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Bybit Crypto Insights Report: Aster Takes on Hyperliquid in the Perp DEX Boom
|
OXFORD, United Kingdom and HOUSTON, June 5, 2026 /PRNewswire/ -- Optellum, a leader in AI-enabled lung cancer diagnostics, today announced that it has surpassed 250 clinical sites and analyzed more than 3 million cases to date. This milestone underscores Optellum's commitment to empowering health systems and clinical care teams with the tools needed to identify, prioritize, and manage high-risk lung nodules more effectively. This commercial momentum is supported by first-of-their-kind partnerships across major markets, including with Bristol Myers Squibb in the US, and with the NHS and Intuitive Surgical to support end-to-end AI & robot lung cancer pathways in the UK. It is also reflected in established and new customer deployments at leading health systems, including the University of Pennsylvania Health System, Vanderbilt University Medical Center, and Oxford University Hospitals.
The scale of Optellum's impact is accelerating rapidly, and the company is now helping one patient every 14 seconds. Optellum pioneered the world's first FDA-cleared, CE-marked, and Medicare-reimbursed AI solution for image-based lung cancer risk stratification – Lung Cancer Prediction (LCP) AI, under the CPT codes 0721T and 0722T. LCP AI is helping to reduce the uncertainty associated with indeterminate lung nodules, ensuring that no nodule patient is left behind. Further, the wraparound Virtual Nodule Clinic (VNC) solution supports guideline-aligned decisions and has been shown to improve clinicians' efficiency while reducing time to recommended treatment.[1]
This growth reflects a broader shift toward the adoption of evidence-based innovation in thoracic care. Optellum continues to expand LungOSⓇ, its end-to-end AI-powered lung health platform, powered by the world's first Thorax CT Foundation Model built for real-world precision lung care. This foundation model is the only model in the world to leverage DART, the world's largest lung cancer CT dataset. LungOSⓇ brings VNC together with modules for triage and detection,[2] diagnostic support,[3] and therapy guidance.[4] Looking ahead, Optellum is poised to expand its clinical suite with the upcoming European launch of LungDetect, an exciting addition designed to simplify and accelerate nodule identification and characterization.
"Optellum is incredibly proud to be helping more health systems and clinicians provide timely, life-saving care to a growing number of patients," said Dr. Johnathan Watkins, Optellum's CEO. "Reaching 250 sites and analyzing millions of cases each year is a testament to the dedication of our team and the trust of our clinical partners. However, we are just getting started; we continue to build LungOSⓇ into the must-have "operating system" for lung cancer and thoracic care more broadly. We invite the global healthcare community to join us on our mission to help solve lung cancer by ensuring early diagnosis and early intervention become the standard for everyone everywhere."
Results from Optellum's continued growth and real-world clinical use will continue to be shared with clinicians, healthcare leaders, and policymakers to reach the broader goal of improving outcomes for every thoracic care team, in every hospital, for every patient.
About Optellum
Optellum is a commercial-stage AI healthcare company dedicated to revolutionizing early diagnosis and treatment of lung disease, starting with one of the deadliest, lung cancer.
Optellum is building LungOSⓇ, the end-to-end AI-powered platform for thoracic care. Its flagship product, Virtual Nodule Clinic (VNC) with Lung Cancer Prediction AI (LCP), is the world's first FDA-cleared and reimbursed software-as-a-medical-device (SaMD) solution for AI-powered lung cancer prioritization and diagnostic support. Clinicians trust the Optellum solution to aid them in making the most appropriate life-saving treatment decisions for their patients. Backed by real-world clinical evidence, Optellum's solution accelerates the diagnostic care pathway by enabling early patient identification, enhancing prioritization, and improving clinicians' efficiency, reducing time to guideline-recommended treatment. Optellum VNC is FDA cleared, CE-MDR marked, UKCA marked, and TGA-approved.
Optellum is headquartered in Oxford, UK, and has an office in Houston, Texas, US.
[1] Hill NR et al. Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study. BMJ Open Respiratory Research. 2025;12: e003225. https://doi.org/10.1136/bmjresp-2025-003225
[2] Both text-based detection with Patient Discovery and Patient Safety Net as well as image-based detection. Product availability depends on your region, please contact Optellum for more information.
[3] Commercially available in the US, EU/UK, and Australia.
[4] Pending; for research use only
Media Contact
marketing@optellum.com
OXFORD, United Kingdom and HOUSTON, June 5, 2026 /PRNewswire/ -- Optellum, a leader in AI-enabled lung cancer diagnostics, today announced that it has surpassed 250 clinical sites and analyzed more than 3 million cases to date. This milestone underscores Optellum's commitment to empowering health systems and clinical care teams with the tools needed to identify, prioritize, and manage high-risk lung nodules more effectively. This commercial momentum is supported by first-of-their-kind partnerships across major markets, including with Bristol Myers Squibb in the US, and with the NHS and Intuitive Surgical to support end-to-end AI & robot lung cancer pathways in the UK. It is also reflected in established and new customer deployments at leading health systems, including the University of Pennsylvania Health System, Vanderbilt University Medical Center, and Oxford University Hospitals.
The scale of Optellum's impact is accelerating rapidly, and the company is now helping one patient every 14 seconds. Optellum pioneered the world's first FDA-cleared, CE-marked, and Medicare-reimbursed AI solution for image-based lung cancer risk stratification – Lung Cancer Prediction (LCP) AI, under the CPT codes 0721T and 0722T. LCP AI is helping to reduce the uncertainty associated with indeterminate lung nodules, ensuring that no nodule patient is left behind. Further, the wraparound Virtual Nodule Clinic (VNC) solution supports guideline-aligned decisions and has been shown to improve clinicians' efficiency while reducing time to recommended treatment.[1]
This growth reflects a broader shift toward the adoption of evidence-based innovation in thoracic care. Optellum continues to expand LungOSⓇ, its end-to-end AI-powered lung health platform, powered by the world's first Thorax CT Foundation Model built for real-world precision lung care. This foundation model is the only model in the world to leverage DART, the world's largest lung cancer CT dataset. LungOSⓇ brings VNC together with modules for triage and detection,[2] diagnostic support,[3] and therapy guidance.[4] Looking ahead, Optellum is poised to expand its clinical suite with the upcoming European launch of LungDetect, an exciting addition designed to simplify and accelerate nodule identification and characterization.
"Optellum is incredibly proud to be helping more health systems and clinicians provide timely, life-saving care to a growing number of patients," said Dr. Johnathan Watkins, Optellum's CEO. "Reaching 250 sites and analyzing millions of cases each year is a testament to the dedication of our team and the trust of our clinical partners. However, we are just getting started; we continue to build LungOSⓇ into the must-have "operating system" for lung cancer and thoracic care more broadly. We invite the global healthcare community to join us on our mission to help solve lung cancer by ensuring early diagnosis and early intervention become the standard for everyone everywhere."
Results from Optellum's continued growth and real-world clinical use will continue to be shared with clinicians, healthcare leaders, and policymakers to reach the broader goal of improving outcomes for every thoracic care team, in every hospital, for every patient.
About Optellum
Optellum is a commercial-stage AI healthcare company dedicated to revolutionizing early diagnosis and treatment of lung disease, starting with one of the deadliest, lung cancer.
Optellum is building LungOSⓇ, the end-to-end AI-powered platform for thoracic care. Its flagship product, Virtual Nodule Clinic (VNC) with Lung Cancer Prediction AI (LCP), is the world's first FDA-cleared and reimbursed software-as-a-medical-device (SaMD) solution for AI-powered lung cancer prioritization and diagnostic support. Clinicians trust the Optellum solution to aid them in making the most appropriate life-saving treatment decisions for their patients. Backed by real-world clinical evidence, Optellum's solution accelerates the diagnostic care pathway by enabling early patient identification, enhancing prioritization, and improving clinicians' efficiency, reducing time to guideline-recommended treatment. Optellum VNC is FDA cleared, CE-MDR marked, UKCA marked, and TGA-approved.
Optellum is headquartered in Oxford, UK, and has an office in Houston, Texas, US.
[1] Hill NR et al. Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study. BMJ Open Respiratory Research. 2025;12: e003225. https://doi.org/10.1136/bmjresp-2025-003225
[2] Both text-based detection with Patient Discovery and Patient Safety Net as well as image-based detection. Product availability depends on your region, please contact Optellum for more information.
[3] Commercially available in the US, EU/UK, and Australia.
[4] Pending; for research use only
Media Contact
marketing@optellum.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Optellum Celebrates Accelerating Impact in Lung Cancer Care; Now at Over 250 Sites and Growing
